A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/24/2002	CA2444220A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	CA2444148A1 Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
10/24/2002	CA2444047A1 Methods to inhibit viral replication
10/24/2002	CA2443923A1 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	CA2443910A1 Novel use of arylethenesulfonamide derivatives
10/24/2002	CA2443906A1 Novel oral general anesthetics and metabolitically resistant anticonvulsants
10/24/2002	CA2443900A1 Methods of treating prion disease in mammals comprising administering a chaotropic agent such as guanidine, urea or potassium iodide
10/24/2002	CA2443874A1 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
10/24/2002	CA2443870A1 Cyclohexylphenyl vasopressin agonists
10/24/2002	CA2443805A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	CA2443734A1 Method of inhibiting adhesion formation
10/24/2002	CA2443732A1 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443655A1 Tropane alkaloid multidrug resistance inhibitors from erythroxylum pervillei and use of the same
10/24/2002	CA2443639A1 Compositions containing imidazotriazinone for nasal application
10/24/2002	CA2443577A1 Nicotinic acetylcholine receptor ligands
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443567A1 Novel tricyclic pyridyl benzazepine carboxamides and derivatives thereofas tocolytic oxytocin receptor antagonists
10/24/2002	CA2443566A1 Novel 10-cyclohexenyl-phenyl pyrrolobenzodiazepine-3-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443565A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	CA2443564A1 Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
10/24/2002	CA2443563A1 Nail compositions and methods of administering same
10/24/2002	CA2443559A1 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
10/24/2002	CA2443525A1 Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis c virus infections
10/24/2002	CA2443490A1 Tricyclic diazepines as tocolytic oxytocin receptor antagonists
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443473A1 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
10/24/2002	CA2443471A1 An effervescent solid composition of matter
10/24/2002	CA2443470A1 3,7-diazabicyclo [3.3.1] formulations as antiarhythmic compounds
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443464A1 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2443229A1 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
10/24/2002	CA2443147A1 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002	CA2443141A1 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	CA2443123A1 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002	CA2443052A1 Use of cationic dextran derivatives for protecting dose-limiting organs
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2442670A1 Method of treating or retarding the development of blindness
10/24/2002	CA2442626A1 Articles comprising a mint odor-free cooling agent
10/24/2002	CA2442264A1 A method of treating cancer
10/24/2002	CA2442118A1 Improved edible compositions for lowering cholesterol
10/24/2002	CA2441274A1 Aurones as telomerase inhibitors
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2433949A1 Compositions and methods for treating an arthritic condition
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	WO2001095940A1 Sustained release compositions
10/23/2002	WO2001081331A1 Hydrates and crystals of a neuraminic acid compound
10/23/2002	WO2001080854A1 Activators for peroxisome proliferator-activated receptor
10/23/2002	EP1251170A2 Method and reagent for treatment of NF-kappaB dependent animal diseases
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1251132A1 Synthesis of (3aS)-5,5-dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine
10/23/2002	EP1251131A2 Carbamate analogs of thiaphysovenine, pharmaceutical compositions, and method for inhibiting cholinesterases
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1251127A1 Novel sidechain-bearing taxanes and intermediates thereof
10/23/2002	EP1251125A2 New camptothecin analogues, preparation methods thereof, use thereof as drugs, and pharmaceutical compositions containing them
10/23/2002	EP1251120A1 Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl
10/23/2002	EP1250941A1 Articles comprising a mint odor-free cooling agent
10/23/2002	EP1250937A2 Controlled dissolution of active ingredients
10/23/2002	EP1250935A1 REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST
10/23/2002	EP1250934A1 Anticancer compositions
10/23/2002	EP1250928A1 Cancer cell implantation inhibitors
10/23/2002	EP1250927A2 Pharmaceutical composition for topical application comprising nifedipine
10/23/2002	EP1250926A2 Use of a water-insoluble S-camptothecin with a closed lactone ring in the manufacture of a medicament for treatment of colon cancer
10/23/2002	EP1250925A2 Nasal spray containing ondansetron hydrochloride
10/23/2002	EP1250924A1 Eye drops
10/23/2002	EP1250923A2 Use of selective PDE10 inhibitors for the treatment of central nervous system disorders
10/23/2002	EP1250921A1 Fast disintegrating meloxicam tablet
10/23/2002	EP1250920A1 Unloaded ion exchange resins for the extended release of active ingredients
10/23/2002	EP1250919A1 Gelling, relaxing bath compositions
10/23/2002	EP1250917A2 Compositions for the control of microorganisms, comprising primary and secondary esters of polyglycerol in an effective ratio
10/23/2002	EP1250842A1 Composition for controlling microorganisms containing an effective amount of polyglycerinesters
10/23/2002	EP1250455A1 Antisense inhibition of ptp1b expression
10/23/2002	EP1250434A2 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
10/23/2002	EP1250425A2 Secreted human proteins, polynucleotides encoding them and methods of using the same
10/23/2002	EP1250422A2 Myeloid colony stimulating factor and uses thereof
10/23/2002	EP1250348A1 Antisense modulation of daxx expression
10/23/2002	EP1250347A1 Antisense modulation of akt-3 expression
10/23/2002	EP1250343A1 Azalide antibiotic compositions
10/23/2002	EP1250340A1 Methods and compounds for inhibiting mrp1
10/23/2002	EP1250338A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors
10/23/2002	EP1250337A1 Substituted homopiperidinyl benzimidazole analogues as fundic relaxants
10/23/2002	EP1250332A1 Inhibitors of interleukin 5 gene expression
10/23/2002	EP1250331A1 Formulation for protection against oxidative stress containing benzofuranone derivatives
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250326A2 Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250323A2 Compounds having hypolipidemic and hypocholesterolemic activities, process for their preparation and pharmaceutical compositions containing them
10/23/2002	EP1250322A1 Isolation of carotenoid crystals
10/23/2002	EP1250321A1 Glyburide composition
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250313A1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
10/23/2002	EP1250166A1 Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250156A1 Method for nucleic acid transfection of cells
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250153A2 TREATMENT OF i C. DIFFICILE /i TOXIN B ASSOCIATED CONDITIONS
10/23/2002	EP1250152A1 Hyaluronic acid in the treatment of cancer

1 ... 5672 5673 5674 5675 5676 5677 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 ... 7860